TransMedics Group, Inc. (TMDX) Debt to Equity Ratio: 0.99
Is TransMedics Group, Inc.’s debt to equity ratio high or low?
TransMedics Group, Inc.'s debt to equity ratio of 0.99 is 29% below its 5-year average of 1.39, near the low end of its 5-year range (0.33–3.76).
As of Saturday, June 20, 2026. 39.26% below its 12-month average of 1.63.
TMDX Debt to Equity Ratio Chart
TMDX Average Debt to Equity Ratio Chart
TMDX Current vs Average Debt to Equity Ratio Chart
TMDX Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.99
DEBT TO EQUITY RATIO AVG TTM
1.63
DEBT TO EQUITY RATIO AVG 3Y
1.85
DEBT TO EQUITY RATIO AVG 5Y
1.39
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-39.26%
CURRENT VS 3Y AVG
-46.34%
CURRENT VS 5Y AVG
-28.95%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 0.99 | 1.63 | 1.85 | 1.39 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 1.84 | 1.50 | 1.07 | 0.87 |
| 23andMe Holding Co. (ME)vs › | $15.31M | -2.56 | 0.27 | 0.25 | 0.34 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 0.21 | 0.21 | 0.18 | 0.13 |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 2.07 | 1.04 | 0.53 | 0.36 |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 2.70 | 5.51 | 5.51 | 5.51 |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 0.97 | 0.88 | 0.91 | 0.99 |
| Baxter International Inc. (BAX)vs › | $10.27B | 1.63 | 1.78 | 2.05 | 1.83 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 3.23 | 2.45 | 1.88 | 1.68 |
| Revvity, Inc. (RVTY)vs › | $11.16B | 0.48 | 0.45 | 0.51 | 0.56 |
Financial Health
Debt/Equity
0.99
Current Ratio
7.14
TransMedics Group, Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for TransMedics Group, Inc. (TMDX)?
- The debt to equity ratio for TMDX stock is 0.99.
- Is TransMedics Group, Inc.'s debt to equity ratio high or low?
- TransMedics Group, Inc.'s debt to equity ratio of 0.99 is 29% below its 5-year average of 1.39, near the low end of its 5-year range (0.33–3.76).
- What is the TTM average debt to equity ratio for TransMedics Group, Inc. (TMDX)?
- The TTM average debt to equity ratio for TMDX stock is 1.63.
- What is the 3Y average debt to equity ratio for TransMedics Group, Inc. (TMDX)?
- The 3Y average debt to equity ratio for TMDX stock is 1.85.
- What is the 5Y average debt to equity ratio for TransMedics Group, Inc. (TMDX)?
- The 5Y average debt to equity ratio for TMDX stock is 1.39.
TransMedics Group, Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.99 |
| 2024-12-31 | 2.27 |
| 2023-12-31 | 3.76 |
| 2022-12-31 | 0.36 |
| 2021-12-31 | 0.65 |
| 2020-12-31 | 0.33 |
| 2019-12-31 | 0.62 |
| 2016-12-31 | 0.22 |
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein